Global Breast Cancer Liquid Biopsy Market - 2020-2027
発行: DataM Intelligence
ページ情報: 英文 180 Pages
世界の乳がん向けリキッドバイオプシー (液体生検) の市場規模は、乳がんの発症率の上昇や、非侵襲的手法の需要増加、がんに対する関心の増大、さらには各国政府やWHO (世界保健機構) による積極的な取り組みなどの要因を受けて、予測期間中 (2020年～2027年) も拡大傾向が続く見通しです。製品種類別では試薬・キットが最大のセグメントであり、循環バイオマーカー別では循環cfDNAが最も急速に成長すると予測されています。地域別に見ると、北米諸国が最大の市場となる一方、アジア太平洋でも急速な市場成長が生じる見通しです。
The global breast cancer liquid biopsy market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
A biopsy is a tissue or cell sample that is taken from any part of the patient's body and examined in the lab to detect cancer. Liquid biopsy offers a real-time approach for the treatment of breast cancer. It is used for the collection and analysis of a sample of blood taken from the patient. Liquid biopsy uses body fluids as a sample for analysis, primarily blood. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, cell-free DNA (cfDNA) and their cargo proteins, and circulating cell-free RNA (cfRNA). A liquid biopsy is a non-invasive, simple, and cost-effective diagnostic tool for cancer. The number of circulating biomarkers differ among cancer patients and healthy individuals. Therefore, these circulating biomarkers act as an essential tool for early diagnosis and monitoring of disease progression in advanced cancer stages to analyze the heterogeneity of tumor cells. Moreover, the breast cancer liquid biopsy test detects epidermal growth factor receptor (EGFR) gene mutations that support clinicians to choose the proper breast cancer treatment at the right time. Breast cancer is considered the second most common malignancy in the world, and therefore, liquid biopsy is an important tool for breast cancer diagnosis and determination.
The global breast cancer liquid biopsy market growth is driven by the increasing prevalence of breast cancer cases, increase in demand for non-invasive procedures, growing awareness about cancer, increase in health care expenditure, and initiatives and measures taken by government and global health organizations. Moreover, increased intensive research and development in the field of cancer, technological advancements, and an increase in demand toward personalized medicine are key factors to drive the growth of the market.
Increasing prevalence of breast cancer cases, is expected to drive the global Breast cancer liquid biopsy market growth.
The incidence of breast cancers is proliferating. According to the World Health Organization (WHO) scenario, breast cancer is the second most cancer occurring among women. It affects nearly 2.1 million women each year. The American Cancer Society's estimates for breast cancer in the United States for 2021 are that about 281,550 new cases of invasive breast cancer will be diagnosed in women. According to Breast Cancer Care, WA Incorporated in 2019; an estimated 19,371 Australian women were diagnosed with the breast cancer or approximately 53 each day, which accounts for roughly 14% of all new breast cancer cases are diagnosed; furthermore, according to Cancer Research UK, breast cancer is the most common cancer in United Kingdom, accounting for nearly 15% of all the new cancer cases.
Initiative programs undertaking by the government to improve clinical awareness among the common people, is expected to drive the global Breast cancer liquid biopsy market growth.
By Indian Cancer Society: Cancer Awareness Campaign 2019
The campaign is called "Raho cancer se do Kadam aage,"aims to create cancer awareness amongst the population of India. It is essential to destroy the myths that people wrongly believe, inform them about the signs and symptoms and the importance of screening for early detection. It is also essential to follow a healthy lifestyle, and sharing survivor stories give hope and confidence.
National Comprehensive Cancer Control Program. More than 98,000 people have been involved in cancer coalitions, and Sixty-nine cancer plans have been created and updated.
National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Through the NBCCEDP, CDC helping low-income, uninsured, and underinsured women to gain access to frequent breast and cervical cancer screening, diagnostic, and treatment services. . During 2016-2017, about 5.3% of U.S. women were eligible for this program, breast cancer screening services, and the program served 15.0% of qualified women.
High cost of treatment in low- income countries is likely to hinder the market growth
Health-care expenditure for breast cancer is quite high. It has been estimated that by 2035, the United States will spend approximately between 3.6 and 7.6 trillion dollars on patients with the breast cancer. With low-income countries providing only 20% of health insurance reimbursements, it is becoming difficult for people to afford the bills and opt for minimally invasive surgeries. For instance, as per the National Library of Medicine, the Procedure-related costs were $368.5 and the incremental treatment cost with liquid biopsy was US $7,333.17.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on the Product Type, the global Breast Cancer Liquid Biopsy market is segmented into Reagents and Kits, Instruments, Others.
Reagents and Kits segment accounts the largest market share among all the segments.
Reagents are playing a vital role in the In-vitro cancer diagnostics market. It includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Increase in number of breast cancer liquid biopsy test procedures, surge in demand for reagent kits, increase in breast cancer liquid biopsy reagent kit approvals. For instance, On November 9, 2019, Lexent Bio signed a partnership with Illumina, Inc. to develop a next-generation sequencing IVD kit to diagnose cancer. In September 2019, Sysmex Inostics announced the launch of "SafeSEQ" liquid biopsy panels for breast and head & neck cancer, along with the availability of the "SafeSEQ Rapid Custom Development" program designed for identification and analysis of circulating tumor DNA. The test has been optimized to offer highest levels of accuracy, and sensitivity in different biopsy processes.
The instrument segment is expected grow slowly, advanced instruments and rapid testing tools are driving the segment. For instance, BioNTech Diagnostics GmbH develops and manufactures the biomarker-based in vitro diagnostic devices (IVDD) like MammaTyper for Invasive breast cancer is under clinical trials.
Based on the circulating biomarkers, the global Breast Cancer Liquid Biopsy market is segmented into circulating tumor cells (CTC's), circulating cell-free DNA (cfDNA), extracellular vesicles, and other circulating biomarkers.
The circulating cell-free DNA segment is expected to grow at the fastest CAGR during the forecast period (2020-2027). The Circulating cell-free DNA (cfDNA) in plasma offers a non-invasive approach to monitor tumor molecular profiling in real-time at multiple time points, detect emerging genomic alterations associated with drug resistance, and clarify cancer prognosis and diagnosis of cancer recurrence or progression. Many companies offer cfDNA based products for use in research purposes. For instance, Hilden, Germany-based Qiagen, offers the QIAamp circulating nucleic acid kit used in a column-based method to isolate cfDNA from plasma and serum. Genomics for Life Pty Ltd is a Queensland, Australia-based company that offers genetic testing for cfDNA from blood samples. It is a major private-sector company that provides cfDNA-based testing services in Australia.
Based on End-Users, the global Breast Cancer Liquid Biopsy market is segmented into Reference laboratories, Hospitals and Physician laboratories, and Others
The reference laboratories segment accounts the largest share of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories. This is due to a rise in the number of liquid biopsy test samples received by reference laboratories for genetic testing.
North America region holds the largest share in the global breast cancer liquid biopsy market. This is primarily due to rising incidences of breast cancer and the growing demand for non-invasive treatment in this region. According to the National Breast Cancer Foundation of the United States, in 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represented approximately 15.2% of all new cancer cases in the United States. In the United States, Biocept, a molecular oncology diagnostics company, offers advanced methods for detecting circulating cancer cells (CTCs) and oncogene mutation fragments (ctDNA) in the blood. This allows CLIA-certified and CAP-accredited laboratories to perform predictive biomarker testing and provide the most up-to-date biomarker status from a non-invasive patient blood sample in breast cancer diagnosis up opportunities in breast cancer liquid biopsy.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations.
The global breast cancer liquid biopsy market is quite competitive with some key competitors like QIAGEN, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Janssen Diagnostics, Guardant Health, Inc, Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences, Inc and Illumina, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, In January 2021, Biodesix announced an agreement with HiberCell to conduct further development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic test.
Overview: QIAGEN, founded in 1984, is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Currently, 5,300 employees. Founded by the three young scientists, Metin Colpan, Karsten Henco, and Jurgen Schumacher, and their doctoral supervisor Detlev Riesner, their goal was to establish a research outfit supplying products for molecular biological research. In 2004, QIAGEN's QIAamp became the world's first standalone product for sample preparation to receive the CE-mark. In 2007, QIAGEN merged with Digene Corp., creating the market and technology leader in molecular diagnostics. In 2018, Collaborations with more than 25 pharmaceutical and biotech companies to develop companion and complementary diagnostics to guide clinical decision-making solidified QIAGENs leading position in precision medicine.
Product Portfolio: The company portfolio includes Oncology, Liquid Biopsy, Infectious disease, Next-generation sequencing, Molecular biology research, Genomic services, Digital PCR.
Two new FDA-approved tests are added to QIAGEN's companion diagnostic portfolio: The therascreen PIK3CA RGQ PCR Kit aids in identifying patients eligible for a new breast cancer therapy developed by Novartis and the therascreen FGFR RGQ RT-PCR Kit identifies urothelial cancer patients for Janssen Biotech's newly approved FGFR kinase inhibitor.
The global breast cancer liquid biopsy market report would provide an access to an approx. 61 market data table, 50 figures and 300 pages.
LIST NOT EXHAUSTIVE